Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PPM1D | O15297 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6772886 | 1.00 | CA12 (0.35) | CA12CA9CA1CA2PREP | |
| SCHEMBL25758895 | 1.00 | CA12 (0.35) | CA12CA9CA1CA2PREP | |
| SCHEMBL7659117 | 1.00 | CA12 (0.35) | CA12CA9CA1CA2PREP | |
| SCHEMBL11548963 | 1.00 | CA12 (0.35) | CA12CA9CA1CA2PREP | |
| SCHEMBL7441811 | 1.00 | CA12 (0.35) | CA12CA9CA1CA2PREP | |
| SCHEMBL14440399 | 1.00 | CA12 (0.35) | CA12CA9CA1CA2PREP | |
| SCHEMBL14440425 | 1.00 | CA12 (0.35) | CA12CA9CA1CA2PREP | |
| SCHEMBL7679245 | 0.87 | CA12 (0.35) | CA12CA9CA1CA2PREP | |
| SCHEMBL6772879 | 0.84 | — | — | |
| SCHEMBL17694215 | 0.84 | CA12 (0.34) | CA12CA9CA1CA2PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174477-A1 | METHODS FOR SYNTHESIS OF THE TRICYCLIC PROSTAGLANDIN D2 METABOLITE METHYL ESTER | PURDUE RESEARCH FOUNDATION | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174477-A1 | METHODS FOR SYNTHESIS OF THE TRICYCLIC PROSTAGLANDIN D2 METABOLITE METHYL ESTER | PTGES2, PTGDR2, PTGES | CA12 1162/4885CA9 2746/4885CA1 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.